Skip to main content

Corey Hopkins Archives

Collaboration seeks to develop new therapies for bone, other diseases

Oct. 1, 2015—La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders.

Read more


Growth factor blockade targets breast tumors

Aug. 14, 2014—Inhibition of BMP growth factor signaling reduces breast tumor burden and metastasis.

Read more


Small molecule protects kidney filter

Mar. 19, 2014—A compound identified at Vanderbilt has therapeutic potential in protecting the kidney filter barrier.

Read more


VU researcher has personal motive for investigating malaria

Feb. 3, 2012—Vanderbilt researcher and Gabon, Africa, native is working to discover ways to kill malaria-spreading mosquitoes.

Read more


Drug-like molecules aimed at improving treatment of Parkinson’s

Sep. 30, 2011—Drug-like molecules described by Vanderbilt researchers could lead to Parkinson's treatments with fewer side effects.

Read more


Upcoming Events

MORE EVENTS »